Evotec AG O.N. (EVTG)

23.230
-0.330(-1.40%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    23.230 - 23.590
  • Type:Equity
  • Market:Austria
  • ISIN:DE0005664809

EVTG Overview

Prev. Close
28.48
Day's Range
23.23-23.59
Revenue
-
Open
23.59
52 wk Range
20.94-45.74
EPS
-
Volume
0
Market Cap
4.34B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
204
P/E Ratio
-
Beta
-
1-Year Change
-35.65%
Shares Outstanding
176,702,738
Next Earnings Date
Aug 11, 2022
What is your sentiment on Evotec AG?
or
Market is currently closed. Voting is open during market hours.

Evotec AG O.N. Analysis

Evotec AG O.N. Company Profile

Evotec AG O.N. Company Profile

Employees
4198
Market
Germany

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Read More

Technical Summary

Type
Daily
Weekly
Monthly
Moving AveragesSellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong Sell
  • To be fair the stock has had large (lazy) short positions for many months and the US DoD deal is not new news. Also, the sceince of  monoclonal antibodies is still not proven. That said, as a pipeline of royalties begin to come through adding to top lines my outlook remains  €50 target in 3 years.
    0
    • lol railing Melvin Capital left and right
      0
      • Doesnt have anything to do with that here but rather the us military filing in a huge order at evotec for anti bodies against covid (over the next 7 years)
        0
    • The valuation is very much a "sum of the parts" not a not a future valuation. The potentials from a series of bolt on company purchases and ongoing strategic alliances will see a valuation of €10Bn within the next 5 years. What is not priced in to the current valuation is the vision of the management  and shear quality of the science.. . Volatility is an issue so hold on to your hat !!. . Still not convinced ? Where else could you have got 50%+ return on stocks for the past three years ??
      0